Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

CEPI and WHO call for urgent global research to prepare for the next pandemic

The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) today called on researchers and governments to strengthen and accelerate global research

August 2, 2024

Nobel laureate Carolyn Bertozzi joins cell therapy biotech Acepodia as chief scientific advisor

Carolyn Bertozzi helped kindle the spark that became cell therapy biotech Acepodia while the company’s co-founder, Sonny Hsiao, was still a PhD student, working in

September 19, 2023

Immune cell networks key to success of personalized cancer treatment

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.